Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830264 | 0.85 | ALDH1A1 (0.58) | KDM4EALDH1A1MAPTL3MBTL1NCOA3 | |
| SCHEMBL10496029 | 0.79 | MAPT (0.51) | KDM4EALDH1A1MAPTL3MBTL1NCOA3 | |
| SCHEMBL2125784 | 0.79 | KDM4E (0.49) | KDM4EALDH1A1L3MBTL1CYP1A2MEN1 | |
| SCHEMBL7128183 | 0.76 | CYP1A2 (0.62) | KDM4EALDH1A1L3MBTL1ADRA2AADRA2C | |
| SCHEMBL10810254 | 0.73 | ELANE (0.44) | KDM4EALDH1A1MAPTL3MBTL1CYP1A2 | |
| SCHEMBL30572385 | 0.72 | KDM4E (0.49) | KDM4EALDH1A1MAPTL3MBTL1CYP1A2 | |
| SCHEMBL30572436 | 0.72 | KDM4E (0.49) | KDM4EALDH1A1MAPTL3MBTL1CYP1A2 | |
| SCHEMBL6791707 | 0.70 | MAOA (0.61) | KDM4EALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL5826547 | 0.70 | ALDH1A1 (0.56) | KDM4EALDH1A1MAPTL3MBTL1NCOA3 | |
| SCHEMBL9685540 | 0.70 | ALDH1A1 (0.56) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1468224-A | Quinoline derivatives as alpha-2 antagonists | — | 2004-01-14 | — | — | CN | disclosed |
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ORION CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-6593324-B2 | P-aminoanilino- derivatives | ORION CORPORATION (FI) | 2003-07-15 | — | — | US | disclosed |
| EP-1263733-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION FARMOS (FI) | 2002-12-11 | — | — | EP | disclosed |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2001-11-29 | — | — | US | disclosed |
| WO-2001064645-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION (FI) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | KDM4E 3467/4885ALDH1A1 467/4885MAPT 2548/4885 |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | KDM4E 3467/4885ALDH1A1 467/4885MAPT 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.